These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12627363)

  • 1. The role of clonality in the global spread of fluoroquinolone-resistant bacteria.
    Klugman KP
    Clin Infect Dis; 2003 Mar; 36(6):783-5. PubMed ID: 12627363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Impact of fluoroquinolone use on multidrug-resistant bacteria emergence].
    Nseir S; Ader F; Marquette CH; Durocher A
    Pathol Biol (Paris); 2005; 53(8-9):470-5. PubMed ID: 16176863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Widespread use of fluoroquinolones versus emerging resistance in pneumococci.
    Goldstein EJ; Garabedian-Ruffalo SM
    Clin Infect Dis; 2002 Dec; 35(12):1505-11. PubMed ID: 12471570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance.
    Ferrara AM
    Infection; 2005 Jun; 33(3):106-14. PubMed ID: 15940410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of quinolone action and microbial response.
    Hawkey PM
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():29-35. PubMed ID: 12702701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The quinolones: decades of development and use.
    Emmerson AM; Jones AM
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():13-20. PubMed ID: 12702699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of antimicrobial resistance in pathogenic bacteria from livestock animals.
    Wallmann J
    Int J Med Microbiol; 2006 Jun; 296 Suppl 41():81-6. PubMed ID: 16530479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S; Ianniello F; Leone S; Esposito S
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children?
    Mandell LA; Peterson LR; Wise R; Hooper D; Low DE; Schaad UB; Klugman KP; Courvalin P
    Clin Infect Dis; 2002 Sep; 35(6):721-7. PubMed ID: 12203170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN; Fritsche TR; Sader HS; Stilwell MG
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TARGETed surveillance: susceptibility of Streptococcus pneumoniae isolated from community-acquired respiratory tract infections in 2003 to fluoroquinolones and other agents.
    Morrissey I; Colclough A; Northwood J
    Int J Antimicrob Agents; 2007 Oct; 30(4):345-51. PubMed ID: 17643269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoroquinolone resistance and plasmid addiction systems: self-imposed selection pressure?
    Ellington MJ; Woodford N
    J Antimicrob Chemother; 2006 Jun; 57(6):1026-9. PubMed ID: 16585131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The epidemiology of fluoroquinolone-resistant Neisseria gonorrhoeae in Hawaii, 2001.
    Newman LM; Wang SA; Ohye RG; O'Connor N; Lee MV; Weinstock HS
    Clin Infect Dis; 2004 Mar; 38(5):649-54. PubMed ID: 14986248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The magnitude of the association between fluoroquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported.
    Bolon MK; Wright SB; Gold HS; Carmeli Y
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1934-40. PubMed ID: 15155181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of Pseudomonas aeruginosa.
    Wong-Beringer A; Wiener-Kronish J; Lynch S; Flanagan J
    Clin Microbiol Infect; 2008 Apr; 14(4):330-6. PubMed ID: 18190571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.
    Fuller JD; Low DE
    Clin Infect Dis; 2005 Jul; 41(1):118-21. PubMed ID: 15937772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of recent bacterial isolates to cefdinir and selected antibiotics among children with urinary tract infections.
    Bonsu BK; Shuler L; Sawicki L; Dorst P; Cohen DM
    Acad Emerg Med; 2006 Jan; 13(1):76-81. PubMed ID: 16365328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae.
    Schurek KN; Adam HJ; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2006 Sep; 28(3):266-9. PubMed ID: 16904294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance.
    Doern GV
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):821-35. PubMed ID: 17140358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The changing epidemiology of resistance.
    Hawkey PM; Jones AM
    J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i3-10. PubMed ID: 19675017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.